A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY 5301 in Patients With an Anterior ST-Elevation Myocardial Infarction
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2,351
- 试验地点
- 52
- 主要终点
- Proportion of either cardiovascular mortality or heart failure
研究概览
简要总结
To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
详细描述
The purpose of this study is to evaluate the efficacy and safety of FDY-5301 compared to placebo on cardiovascular clinical outcomes in subjects with an anterior ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI).
The study is designed as a randomized double-blind parallel-group comparison of FDY-5301 and placebo. Inclusion and exclusion criteria have been designed to ensure a broad population including seriously ill patients, with or without prior myocardial infarction or coronary artery bypass graft. Demonstration of efficacy in the anterior STEMI population will translate to all STEMIs agnostic of anatomical location, as the pathophysiology and pharmacology are highly likely to translate from anterior STEMIs to non-anterior STEMIs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Anterior STEMI, based on:
- •Symptoms of myocardial ischemia (such as chest pain, shortness of breath, jaw pain, arm pain, diaphoresis, or any anginal equivalent) and
- •Electrocardiogram (ECG) criteria:
- •men > 40 years: ≥ 2 mm of ST elevation in V2 and V3
- •men ≤ 40 years: ≥ 2.5 mm of ST elevation in V2 and V3
- •women ≥ 1.5 mm of ST elevation in V2 and V3
- •Planned primary PCI to occur ≤ 6 hours of onset of persistent symptoms that caused the patient to pursue medical care for myocardial infarction
- •Institutional Review Board (IRB) / Independent Ethics Committee (IEC) approved consent obtained for study participation
排除标准
- •Life expectancy of less than 1 year due to non-cardiac pathology
- •Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization
- •Known allergy to iodine or the excipient of the investigational product (sodium chloride)
- •Renal disease requiring dialysis
- •Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization
- •Body weight > 140 kg (or 309 lbs)
- •Use of thrombolytic therapy as treatment for the index STEMI event
- •Use of investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to randomization or the use of investigational devices within 30 days prior to randomization
- •Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301
研究组 & 干预措施
FDY-5301
FDY-5301 will be administered as a single IV bolus injection.
干预措施: FDY-5301 (Drug)
Placebo
Placebo (normal saline) will be administered as a single IV bolus injection.
干预措施: Placebo (Other)
结局指标
主要结局
Proportion of either cardiovascular mortality or heart failure
时间窗: Through Month 12
The proportion of subjects who experience either cardiovascular mortality or a heart failure event
次要结局
- All-cause mortality or acute heart failure(Through Month 12)
- Cardiovascular events(Through Month 12)
- Other non-fatal cardiovascular morbidity(Through Month 12)
- Serum troponin T(Day 3)